J9190 is terminated (historical record)
Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J9190
500 MG
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 20 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Clinical: Data |
| Facility outpatient hospital services | 20 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Clinical: Data |
| DME supplier services | 20 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Most recent Medicare Part B payment limit · Q3 2026
$2.024per 500 MG
Effective Jul 1, 2026 – Sep 30, 2026 · ASP methodology (per CMS file) · based on Q1 2026 ASP data · coinsurance 20.000%
Not in the latest payment limit file (Q4 2026). Shown for history only.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $2.024 | 500 MG | 20% | −1.6% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $2.056 | 500 MG | 20% | +5.9% |
Medicare hospital outpatient (OPPS)
No authoritative public data was located for this field.
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
No CMS NDC–HCPCS crosswalk rows were located. CMS notes its crosswalks are not a comprehensive list of all NDCs.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 16729-0276-38 | FluorouracilAccord Healthcare Inc | 100 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 16729-0276-68 | FluorouracilAccord Healthcare Inc | 10 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | ListedFluorouracil |
| 16729-0276-11 | FluorouracilACCORD HEALTHCARE INC | 50 × 1 | 5 | 5 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFluorouracil |
| 16729-0276-67 | FluorouracilACCORD HEALTHCARE INC | 20 × 10 | 2 | 20 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFluorouracil |
| 62332-0751-50 | FluorouracilAlembic Pharmaceuticals Inc. | 50 × 1 | 5 | 5 | ASP | Q4 2023 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 62332-0779-31 | FluorouracilAlembic Pharmaceuticals Inc. | 100 × 1 | 10 | 10 | ASP | Q3 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 68001-0266-32 | FluorouracilAMERICAN HEALTH PACKAGING | 100 × 1 | 10 | 10 | ASP | Q4 2022 – Q4 2024Not in Q4 2026 file | Excluded listingFluorouracil |
| 68001-0524-30 | FluorouracilBluePoint Laboratories | 10 × 10 | 1 | 10 | ASP | Q4 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 68001-0524-31 | FluorouracilBluePoint Laboratories | 20 × 10 | 2 | 20 | ASP | Q2 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 68001-0525-27 | FluorouracilBluePoint Laboratories | 50 × 1 | 5 | 5 | ASP | Q2 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 68001-0525-32 | FluorouracilBluePoint Laboratories | 100 × 1 | 10 | 10 | ASP | Q2 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 68001-0627-27 | FluorouracilBluePoint Laboratories | 50 × 1 | 5 | 5 | ASP | Q3 2025 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 68001-0628-32 | FluorouracilBluePoint Laboratories | 100 × 1 | 10 | 10 | ASP | Q3 2025 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 55150-0498-01 | FluorouracilEugia US LLC | 50 × 1 | 5 | 5 | ASP | Q1 2026 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 55150-0499-01 | FluorouracilEugia US LLC | 100 × 1 | 10 | 10 | ASP | Q2 2026 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-10 | FluorouracilFreseniUS Kabi USA, LLC | 10 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-18 | FluorouracilFreseniUS Kabi USA, LLC | 10 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-19 | FluorouracilFreseniUS Kabi USA, LLC | 10 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | Excluded listingFluorouracil |
| 63323-0117-20 | FluorouracilFreseniUS Kabi USA, LLC | 20 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-28 | FluorouracilFreseniUS Kabi USA, LLC | 20 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | Excluded listingFluorouracil |
| 63323-0117-51 | FluorouracilFreseniUS Kabi USA, LLC | 50 × 1 | 5 | 5 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-58 | FluorouracilFreseniUS Kabi USA, LLC | 50 × 1 | 5 | 5 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-59 | FluorouracilFreseniUS Kabi USA, LLC | 50 × 1 | 5 | 5 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-61 | FluorouracilFreseniUS Kabi USA, LLC | 100 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-68 | FluorouracilFreseniUS Kabi USA, LLC | 100 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 63323-0117-69 | FluorouracilFreseniUS Kabi USA, LLC | 100 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 71288-0154-76 | FluorouracilMeitheal Pharmaceuticals Inc. | 100 × 1 | 10 | 10 | ASP | Q4 2025 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 71288-0170-75 | FluorouracilMeitheal Pharmaceuticals Inc. | 50 × 1 | 5 | 5 | ASP | Q2 2025 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 25021-0215-98 | FluorouracilSagent Pharmaceuticals | 50 × 1 | 5 | 5 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 25021-0215-99 | FluorouracilSagent Pharmaceuticals | 100 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 00703-3015-13 | AdrucilSICOR PHARMACEUTICALS, INC. | 10 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingAdrucil |
| 00703-3018-12 | AdrucilSICOR PHARMACEUTICALS, INC. | 50 × 5 | 5 | 25 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingAdrucil |
| 00703-3019-12 | AdrucilSICOR PHARMACEUTICALS, INC. | 100 × 5 | 10 | 50 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingAdrucil |
| 70700-0186-23 | FluorouracilXiromed, LLC | 10 × 10 | 1 | 10 | ASP | Q1 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 70700-0187-23 | FluorouracilXiromed, LLC | 20 × 10 | 2 | 20 | ASP | Q1 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 70700-0188-22 | FluorouracilXiromed, LLC | 50 × 1 | 5 | 5 | ASP | Q1 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
| 70700-0189-22 | FluorouracilXiromed, LLC | 100 × 1 | 10 | 10 | ASP | Q1 2024 – Q3 2026Not in Q4 2026 file | ListedFluorouracil |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q4 2026 | Termination date set | D — Discontinued | Termination date Sep 30, 2026 |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1984 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Clinical: Data |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.941 | 500 MG | 20% | −2.5% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.990 | 500 MG | 20% | +16.0% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.715 | 500 MG | 20% | −22.3% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $2.206 | 500 MG | 20% | −1.1% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $2.230 | 500 MG | 20% | −6.9% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $2.394 | 500 MG | 20% | −25.6% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $3.219 | 500 MG | 20% | +9.1% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $2.951 | 500 MG | 20% | −8.2% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $3.215 | 500 MG | 20% | +13.3% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $2.838 | 500 MG | 20% | +55.1% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $1.830 | 500 MG | 20% | −22.8% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $2.371 | 500 MG | 20% | −5.8% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $2.516 | 500 MG | — | +6.6% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $2.361 | 500 MG | — | +11.1% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $2.126 | 500 MG | — | +18.0% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $1.802 | 500 MG | — | −15.4% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $2.129 | 500 MG | — | +24.9% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $1.704 | 500 MG | — | +9.2% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $1.561 | 500 MG | — | −21.4% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $1.987 | 500 MG | — | +18.0% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $1.684 | 500 MG | — | — | — |
|---|